Table 2 VEN combined with chemotherapy drugs, antibody drugs or targeted drugs for R/R AML

Regimen

VEN + Cladribine + Ara-C

VEN + HAM

VEN + FLAG-IDA

VEN + AZA + PVEK

VEN + PegC

Study type

N/A

Phase-I/II

Phase IIb

Phase 1b/II

Phase Ib

NCT number

NCT05190549

NCT04330820

N/A

NCT04086264

NCT04666649

Study period

2021–2022

2020–2022

N/A

N/A

N/A

Age range (years)

16–68

40–70

18–68

25–82

24–76

Patients number

21

12

33

71

11

Response rate

ORR 90.5%, CR/CRi 28.6%

CR/CRi 92%

ORR 60%

ORR 51%

ORR 64%

Grade ≥ 3 AEs

N/A

0

N/A

Ferbrile neutropenia 24%

0

Follow-up (months)

N/A

N/A

15.8

N/A

N/A

Survival

Median OS and EFS not reached, estimated 1-year OS 91.7%, estimated 1-year EFS 74.9%

N/A

Median OS 27 months, median DOR not reached. Six-month OS 69%, 12-month OS 60%

N/A

N/A